Lumpectomy Sets High Bar For Thermal Ablation Clinical Trials – Panel
This article was originally published in The Gray Sheet
Executive Summary
Interstitial laser therapy developer Kelsey, Inc. is urging FDA to allow the firm to combine its feasibility and pivotal trial phases in conducting research to support a breast cancer treatment indication
You may also be interested in...
FDA Proposes Registry On Thermal Ablation For Breast Cancer
FDA says the development of a patient registry might help industry design better early-stage clinical trials for evaluating ablation as an alternative breast tumor treatment to more invasive surgery
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.